Kymera Results Presentation Deck

KT-413: Phase 1, Multicenter, Dose-Escalation and Expansion Trials to Evaluate KT-413 in Patients with R/R DLBCL 0.16 0.32 Key Objectives Primary ● Ⓡ ● Phase 1a (n up to 40) R/R B-cell NHL Dec. 2022: Currently enrolling 0.51 0.82 Regimen: mg/kg IV Infusion q 3 weeks Predicted clinically efficacious doses Secondary Exploratory PD Effects of KT-413 MTD: Maximum Tolerated Dose. RP2D: Recommended Phase 2 Dose. ORR: Overall Response Rate KYMERA ©2022 KYMERA THERAPEUTICS, INC. DLX Phase 1a Safety/Tolerability and MTD and RP2D PK Parameters of KT-413 Preliminary Estimates of Activity ● ● ● MTD/RP2D Expansion * *Additional 3-6 pts for a total of 9 patients dosed at MTD Phase 1b (n=40) R/R DLBCL PD Effects of KT-413 Cohort 1: MYD88MT n=20 Cohort 2: MYD88WT n=20 Phase 1b Safety/Tolerability at RP2D in Patients with DLBCL Preliminary Clinical Activity (ORR, DOR, PFS, DCR, OS) PK Parameters of KT-413 PAGE 18

View entire presentation